Cargando…
Improved Pharmacokinetic Feasibilities of Mirabegron-1,2-Ethanedisulfonic Acid, Mirabegron-1,5-Naphthalenedisulfonic Acid, and Mirabegron-L-Pyroglutamic Acid as Co-Amorphous Dispersions in Rats and Mice
Mirabegron (MBR) is a β(3)-adrenoceptor agonist used for treating overactive bladder syndrome. Due to its poor solubility and low bioavailability (F), the development of novel MBR formulations has garnered increasing attention. Recently, co-amorphous dispersions of MBR, such as MBR-1,2-ethanedisulfo...
Autores principales: | Kim, Seo-Yeon, You, Byung Hoon, Bae, Mingoo, Han, Seung Yon, Jung, Kiwon, Choi, Young Hee |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10536516/ https://www.ncbi.nlm.nih.gov/pubmed/37765246 http://dx.doi.org/10.3390/pharmaceutics15092277 |
Ejemplares similares
-
Mirabegron: a decade of study
por: Welk, Blayne
Publicado: (2020) -
Inaccuracies in the recently published review on mirabegron
por: Siddiqui, Emad
Publicado: (2013) -
Mirabegron in the Management of Overactive Bladder Syndrome
por: O’Kane, Miriam, et al.
Publicado: (2022) -
Serum sickness–like reaction associated with mirabegron
por: Tan, Marcus G., et al.
Publicado: (2019) -
Distinct Conformations of Mirabegron Determined by MicroED
por: Lin, Jieye, et al.
Publicado: (2023)